GlassScriptPhysician profile
Timothy E Ekpo
NPI 1891003240
$294,597.61
in general payments reported to CMS, 2019-2025
11 companies · $63K in 2025
The $63K reported for 2025 was more than what 89% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $34K · 2021: $31K · 2022: $14K · 2023: $46K · 2024: $85K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $171K · Travel and Lodging: $20K · Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $171,355.52 |
| Travel and Lodging | $20,435.63 |
| Food and Beverage | $1,769.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $170,376.44 | 2022-2025 | Djo Surgical |
| Zimmer Biomet Holdings, INC. | $63,081.77 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Medtronic USA, INC. | $19,919.43 | 2019-2020 | |
| Insight Medical Systems, INC. | $13,782.77 | 2023-2024 | Arvis |
| Smith+Nephew, INC. | $13,266.75 | 2019-2020 | |
| Medtronic, INC. | $10,191.07 | 2021-2022 | |
| Uoc USA INC | $2,627.79 | 2025 | U2 Knee, U2, Uts, Conformity, U-Mii, U2 Revision Stem, Psa, Ustar, U2 Knee |
| Ortho Development Corporation | $985.70 | 2024 | |
| Bioventus LLC | $237.40 | 2023 | Agili-C |
| Abbott Laboratories | $126.86 | 2025 | Proclaim |
| Heraeus Medical, LLC. | $1.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ekpo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.